Phase 2 N=31 Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma
Advanced Melanoma · Unresectable Melanoma
Primary: Overall Response Rate (ORR) — 10 percentage of patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=20 Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy
Melanoma
Primary: Overall Response Rate (ORR) as Defined by RECIST v1.1 at Week 18 — 20; 56 percentage of participants
Phase 2 N=1,009 A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)
Melanoma
Primary: the Incidence of Highgrade (CTCAE v4.0 Grade 3 or Higher), Treatment Related,Select Adverse Events. — 16; 0; 30; 0 Number of Participants
Phase 2 N=10 Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
Unresectable Malignant Neoplasm · Melanoma · Metastatic Melanoma
Primary: Resectability Rate — 8; 2 Participants
Phase 2 N=20 Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Primary: Objective Response Rate Using RECIST v1.1 to Nivolumab and Ipilimumab When Administered in Combination to Patients With Pre-treated Advanced NSCLC Who Have Experienced…
Phase 1 N=155 Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma
Malignant Melanoma
Primary: Investigator-Assessed Objective Response Rate (ORR) — 12.0; 36.4; 38.5 Percentage of Participants
Phase 2 N=27 LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma
Melanoma
Primary: Overall Response — 0; 1; 1; 0 Participants
Phase 2 N=60 Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma
Stage III Melanoma · Stage IV Melanoma · Unresectable Melanoma
Primary: Percentage of Participants With Progression-free Survival at 6 Months — 68 percentage of participants
Phase 2 N=42 BO-112 With Pembrolizumab in Unresectable Malignant Melanoma
Melanoma
Primary: Overall Response Rate — 25.0 percentage of participants — p=<0.01
Phase 2 N=25 Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
Melanoma Stage Iii · Melanoma Stage Iv · Melanoma
Primary: The Antitumor Effect of Denosumab Alone as Represented by the Change in Recent Thymic Emigrant Cells in Peripheral Blood — 2.69; 2.42; 2.55; 1.92 number of cell per…
Phase 2 N=4 Radiation and Combination Immunotherapy for Melanoma
Metastatic Melanoma
Primary: Objective Response Rate (ORR) — 1; 1 Participants
Phase 3 N=270 A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma
Melanoma
Primary: Progression Free Survival (PFS) — 122; 125 days — p=0.492
Phase 2 N=16 Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma
Metastatic Melanoma · Stage IIIB Cutaneous Melanoma AJCC v7 · Stage IIIC Cutaneous Melanoma AJCC v7
Primary: Overall Response Rate in Each Arm — 1; 1; 2; 1 Participants
Phase 3 N=322 GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma
Melanoma
Primary: Progression-free Survival in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases as Assessed by the Investigator and Independent Review…
Phase 2 N=72 Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).
Melanoma
Primary: Objective Response Rate (ORR) Per Modified RECIST v1.1 — 3.8; 6.7; 40.0; 46.7 Percentage of Participants
Phase 2 N=15 Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma
Metastatic Melanoma
Primary: Immune Response Rate — 0.29; 0.67 proportion of participants
Phase 2 N=27 Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker
Melanoma
Primary: Association of Baseline C11-AMT PET SUV Max Value With Objective Response — 6; 6; 1; 13 Participants — p=0.08
Phase 1 N=21 A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade
Advanced or Unresectable Melanoma Progressing After PD1 Blockade
Primary: Incidence of Treatment-emergent Adverse Events Including Treatment-emergent Serious Adverse Events Assessed by Common Terminology Criteria for Adverse Events (CTCAE)…
Phase 2 N=41 Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)
Melanoma · Non-small Cell Lung Cancer · Brain Metastasis
Primary: Brain Metastasis Response Rate (BMRR) — 54.1; 75 percentage of participants
Phase 3 N=676 MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
Melanoma · Metastases
Primary: Overall Survival (OS) (Time-to-Death) Difference Between MDX-010 in Combination With gp 100 Melanoma Peptide Vaccine Versus gp 100 Melanoma Peptide Vaccine Alone — 9.95…
Phase 1 N=62 Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Advanced Solid Tumor
Primary: Number of Participants Experienced Dose Limit Toxicities (DLT) — 0; 0 Participants
Phase 2 N=184 A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment
Melanoma Stage III · Melanoma Stage IV · Unresectable Melanoma
Primary: Arm 1: Objective Response Rate (ORR) — 18.0 percentage of participants — p=0.0148
Phase 2 N=138 PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
Carcinoma, Basal Cell
Primary: Objective Response Rate (ORR) as Assessed by Independent Central Review (ICR) — 22.2; 32.1 Percentage of Participants
Phase 3 N=418 Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma
Melanoma
Primary: Overall Survival (OS) — NA; 10.84 Months — p=<0.0001
Phase 2 N=24 Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery
Metastatic Melanoma · Mucosal Melanoma · Stage IV Cutaneous Melanoma AJCC v6 and v7
Primary: Progression-free Survival (PFS) — 139; 94 days
Phase 2 N=34 Neoadjuvant and Adjuvant Checkpoint Blockade
Cutaneous Melanoma · Mucosal Melanoma · Ocular Melanoma
Primary: Arm C: Number of Participants With the Pathologic Response Rate — 0; 0; 34 Participants
Phase 2 N=24 Trial of pIL-12/MK-3475 in Metastatic Melanoma
Melanoma
Primary: Best Overall Objective Response Rate (ORR) Within 24 Weeks Using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 — 0.375 proportion of participants
Phase 3 N=533 Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma
Melanoma
Primary: Incidence of Participants With High-Grade (CTCAE v4.0 Grade 3-5) Treatment-Related Select Adverse Events — 7; 7; 0; 0 Participants
Phase 2 N=39 Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
Metastatic Uveal Melanoma · Stage IV Uveal Melanoma AJCC v7
Primary: Overall Response Rate, Defined Per RECIST 1.1 — 1; 5; 11; 16 Participants
Phase 2 N=103 Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)
Advanced Melanoma
Primary: Objective Response Rate (ORR) — 21.4 Percentage of Participants